Alkem Laboratories FY26 Annual Earnings Summary

Potential U.S. tariffs could affect pricing and margins; management acknowledged uncertainty and said they will evaluate strategies once tariffs are announced.

The key US launch faces competitive pressure; price erosion could impact US growth trajectory in coming quarters.

Management flagged that R&D spends (4.5-5% of sales) and OpEx from CDMO/medtech initiatives will weigh on H2 margins, potentially offsetting operational improvements.

U.S. business faces ongoing price erosion of 3-4% YoY, which could pressure margins if volume growth does not compensate.

Medtech business expected to break even only by FY28, with losses of INR 40-60 crore in FY26-27; CDMO facility will start contributing meaningfully only from Q4.

Loss of Sikkim facility benefit will result in INR 50-60 crore impact in H2, pressuring margins.

New US CDMO plant will incur ~INR 50 crore quarterly OpEx with only ~INR 20 crore revenue initially, delaying breakeven.

Potential government MIP on penicillin G could increase costs; management declined to comment as it is speculative.

The minimum import price on PenG and its derivatives could impact gross margins by ₹80-100 crore, partially offset by pricing actions in trade generics.

The Occlutech acquisition involves integrating a global Medtech company with different business dynamics, posing execution challenges.

U.S. entry for denosumab biosimilars is delayed to end-2026 due to ongoing litigation with Amgen.

The trade generic business has been flattish this year due to competitive pressures, and recovery to high single-digit growth may take time.